All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Graft-versus-host disease (GvHD) is a common and severe complication observed after allogenic hematopoietic stem cell transplant (allo-HSCT).1 GvHD can be acute (aGvHD) or chronic (cGvHD) depending on the onset and clinical manifestations.2 First-line treatment is based on corticosteroids, but prolonged use is associated with toxicities and development of resistance. Currently, there are only two approved treatments for GvHD: ruxolitinib, indicated for steroid resistant (SR) aGvHD, and ibrutinib, used in patients with cGvHD who have failed one or more lines of therapy. There is currently a strong unmet need for new GvHD treatment options, and many emerging treatments are being tested.
We have reported on the EBMT–ELN working group recommendations for the treatment of aGvHD that were presented at the 1st EBMT GvHD Summit in May 2019. These guidelines have been developed to improve the outcomes of patients with GvHD and are based on the current standard of practice in European hematology centers. Recently, an update of these guidelines has been published in Lancet Haematology.3
The new GvHD Hub editorial theme will focus on novel therapies for the treatment of GvHD. Here are some highlights of the content that the GvHD Hub has previously covered on novel therapies.
Adoptive cell therapy:
At the 24th Congress of the European Hematology Association (EHA), Florent Malard, Hospital Saint-Antoine, Paris, FR, talked to the GvHD Hub about the use of fecal microbiota transplantation in the context of GvHD treatment
Florent Malard | EHA 2019 | How can we better utilize FMT in patients undergoing stem cell transplantation?
Madan Jagasia | ASH 2019 | Is sustained treatment with KD025 required for cGvHD control?
Over the last 15 years, the field of cGvHD has evolved, with the development of novel treatments that are more effective and less toxic. At the 61st ASH Annual Meeting, Steven Pavletic talked about ongoing clinical trials and new drugs for the treatment of cGvHD, such as JAK inhibitors and ROCK inhibitors.
Steven Pavletic | ASH 2019 | What is new in chronic GvHD?
Editorial theme | Latest updates on cGvHD treatment
First-line treatment for chronic graft-versus-host disease (cGvHD), which consists of steroids, has not changed much over the last three decades. In the case of severe cGvHD, another...
An overview of EBMT recommendations on prophylaxis and treatment of acute and chronic GvHD
A summary of the European Society for Blood and Marrow Transplantation (EBMT) webinar entitled ‘Prophylaxis and management of GvHD’ delivered by Olaf Penack on...
Subscribe to get the best content related to GvHD delivered to your inbox